Association Between Sodium-Glucose Cotransporter 2 Inhibitors and Lower Extremity Amputation Among Patients with Type 2 Diabetes
Chang H-Y
JAMA Intern Med 2018;178(9):1190-8
Leggi
Blu
Le Breaking News di colore blu sono relative ad abstract di articoli originali di particolare rilevanza.
Cardiovascular disease prevalence and risk factor prevalence in Type 2 diabetes: a contemporary analysis
McGurnaghan S, Blackbourn LAK, Mocevic E, et al.
Diabet Med. Pub. online September 23, 2018
Leggi
Type 2 diabetes genetic loci informed by multi-trait associations point to disease mechanisms and subtypes: A soft clustering analysis
Udler MS, Kim J, von Grotthuss M, et al.
PLoS Med. Pub. online September 21, 2018
Leggi
Association of Gestational Diabetes With Maternal Disorders of Glucose Metabolism and Childhood Adiposity
Lowe WL Jr, Scholtens DM, Lowe LP, et al.
JAMA. 2018; 320(10):1005-16.
Leggi
Real-World Diabetes Prevention: From Theory to Practice
Ryder REJ
The Lancet Diabetes & Endocrinology. Pub. online 14 September 2018.
Leggi
Successful Treatment of Prediabetes in Clinical Practice Using Physiological Assessment (Stop Diabetes)
Armato JP, DeFronzo RA, Abdul-Ghani M, Ru RJ
The Lancet Diabetes & Endocrinology. Pub. online 14 September 2018.
Leggi
Cardiovascular Safety of Lorcaserin in Overweight or Obese Patients
Bohula EA, Phil D, Wiviott SD, et al.
N Engl J Med. 2018;379(12):1107-17.
Leggi
SGLT2 inhibitors and mechanisms of cardiovascular benefit: a state-of-the-art review
Verma S, McMurray JJV
Diabetologia 2018;61(10):2108-17
Leggi
Use of SGLT2 inhibitors in type 2 diabetes: weighing the risks and benefits
Lupsa BC, Inzucchi SE
Diabetologia 2018;61(10):2118-25
Leggi
Empagliflozin is associated with improvements in liver enzymes potentially consistent with reductions in liver fat: results from randomised trials including the EMPA-REG OUTCOME® trial
Sattar N, Fitchett D, Hantel S, et al.
Diabetologia 2018;61(10):2155-63
Leggi